	US 12,351,859 B2
	Methods for the epigenetic analysis of DNA, particularly cell-free DNA
Patrick A. Arensdorf, Palo Alto, CA (US); and Damek Spacek, Redwood City, CA (US)
Assigned to ClearNote Health, Inc., San Diego, CA (US)
Filed by ClearNote Health, Inc., San Mateo, CA (US)
Filed on Mar. 30, 2023, as Appl. No. 18/192,922.
Application 18/192,922 is a division of application No. 16/275,237, filed on Feb. 13, 2019, granted, now 11,634,748.
Claims priority of provisional application 62/630,798, filed on Feb. 14, 2018.
Prior Publication US 2023/0235380 A1, Jul. 27, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/6806 (2018.01); C07H 19/06 (2006.01); C07H 21/04 (2006.01); C07J 1/00 (2006.01); C12Q 1/6827 (2018.01); C12Q 1/6869 (2018.01)

CPC C12Q 1/6806 (2013.01) [C07H 19/06 (2013.01); C07H 21/04 (2013.01); C07J 1/00 (2013.01); C12Q 1/6827 (2013.01); C12Q 1/6869 (2013.01); C12Q 2523/10 (2013.01); C12Q 2523/115 (2013.01); C12Q 2537/164 (2013.01)]

12 Claims

1. A method for converting an oxidized 5-methylcytosine (5mC) residue selected from 5-carboxylcytosine (5caC) and 5-formylcytosine (5fC) to a dihydrouridine (DHU) residue in cell-free DNA (cfDNA), the method comprising contacting cfDNA containing at least one oxidized 5mC residue selected from 5caC, 5fC, and combinations thereof with pyridine borane.